Abstract: Provided herein are MALT1 inhibitors and the administration of MALT1 inhibitors in subjects such that the efficacy of MALT1 inhibitors is decoupled from the reduction of regulatory T cells. Therefore, the MALT1 inhibitors and methods for administering the MALT1 inhibitors enable the treatment of diseases (e.g., autoimmune diseases) while avoiding reduction of Tregs.
Type:
Application
Filed:
December 9, 2022
Publication date:
January 30, 2025
Applicant:
RARIFIED BIOSCIENCES, INC.
Inventors:
Subhabrata Biswas, Patricia Elaine Rao, Barbara Saxton Fox, Dania Mounir Rabah, Andrew John Long